The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma
Mitotane is the only drug approved to treat adrenocortical carcinoma (ACC), and a relationship of pharmacokinetic/pharmacodynamic has been characterized. However, limited evidence concerning affecting factors in large interindividual variability of the pharmacokinetics of mitotane is available. To a...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2022-06-01
|
| Colección: | Frontiers in Oncology |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fonc.2022.919027/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|